1021919-24-3

Usage

Uses

Used in Pharmaceutical and Chemical Research:
Tert-Butyl 4-bromo-3-methyl-1H-pyrazole-1-carboxylate is utilized as a research compound for its unique structure and potential biological activities. Its presence in pharmaceutical research may be attributed to the pyrazole core, which is common in various bioactive molecules.
Used as an Intermediate in Organic Synthesis:
In the chemical industry, Tert-Butyl 4-bromo-3-methyl-1H-pyrazole-1-carboxylate is employed as an intermediate in the synthesis of other organic compounds. Its functional groups and substituents make it a versatile building block for creating a range of chemical products.
Used in Safety Protocols:
Due to the bromine atom in its structure, Tert-Butyl 4-bromo-3-methyl-1H-pyrazole-1-carboxylate requires careful handling and adherence to safety protocols to minimize potential hazards during its use in laboratories and industrial settings.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 92276-46-5 4-bromo-3-methyl-1⁽²⁾H-pyrazole; hydrobromide 
• 13808-64-5 4-bromo-3-methyl-1H-pyrazole 

Downstream Products

• 936250-20-3 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1009071-34-4 tert-butyl 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate 
• 1140502-26-6 C₂₉H₂₈ClN₅O₄S 

Relevant academic research and scientific papers

BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS

The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules

Compositions and methods which modulate diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including but not limited to cancer, inflammation, and bone related diseases.

THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS

The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer

HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Heteroaryl Compounds having the following structure: (I) wherein R1, R2, L, X, Y, Z, Q, A and B are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

Substituted furo[2,3-B] pyridine derivatives as cannabinoid-1 receptor modulators

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.